Co-targeting of O-GlcNAc transferase (OGT) and the transcriptional kinase cyclin-dependent kinase 9 (CDK9) is toxic to prostate cancer cells. As OGT is an essential glycosyltransferase, identifying an alternative target showing similar effects is of great interest. Here, we used a multiomics approach (transcriptomics, metabolomics, and proteomics) to better understand the mechanistic basis of the combinatorial lethality between OGT and CDK9 inhibition. CDK9 inhibition preferentially affected transcription. In contrast, depletion of OGT activity predominantly remodeled the metabolome. Using an unbiased systems biology approach (weighted gene correlation network analysis), we discovered that CDK9 inhibition alters mitochondrial activity/flux,...
O-GlcNAcylation is a post-translational protein modification overexpressed in the most aggressive pr...
Enormous efforts have been made to target metabolic dependencies of cancer cells for developing new ...
The proteasome is a therapeutic target in cancer, but resistance to proteasome inhibitors often deve...
Co-targeting of O-GlcNAc transferase (OGT) and the transcriptional kinase cyclin-dependent kinase 9 ...
Metabolic networks are highly connected and complex, but a single enzyme, O-GlcNAc transferase (OGT)...
O-GlcNAc transferase (OGT) is a nutrient-sensitive glycosyltransferase that is overexpressed in pros...
Background: Transcription, metabolism and DNA damage response are tightly regulated to preserve the ...
O-GlcNAc transferase (OGT) is overexpressed in aggressive prostate cancer. OGT modifies intra-cellul...
O-GlcNAc is a post-translational modification (PTM) of a single N-acetylglucosamine sugar attachment...
O-GlcNAcylation is an important posttranslational modification governed by a single pair of enzymes–...
Post-translational modification of intracellular proteins with a single N-acetylglucosamine sugar (O...
The expression of O-GlcNAc transferase (OGT) and its catalytic product, O-GlcNAcylation (O-GlcNAc), ...
Background: OGT and AMPK collectively target hundreds of intracellular signaling processes, but no s...
The beta-linked N-acetyl-D-glucosamine (GlcNAc) is a posttranslational modification of serine and th...
Elevated O-GlcNAcylation is associated with disease states such as diabetes and cancer. O-GlcNAc tra...
O-GlcNAcylation is a post-translational protein modification overexpressed in the most aggressive pr...
Enormous efforts have been made to target metabolic dependencies of cancer cells for developing new ...
The proteasome is a therapeutic target in cancer, but resistance to proteasome inhibitors often deve...
Co-targeting of O-GlcNAc transferase (OGT) and the transcriptional kinase cyclin-dependent kinase 9 ...
Metabolic networks are highly connected and complex, but a single enzyme, O-GlcNAc transferase (OGT)...
O-GlcNAc transferase (OGT) is a nutrient-sensitive glycosyltransferase that is overexpressed in pros...
Background: Transcription, metabolism and DNA damage response are tightly regulated to preserve the ...
O-GlcNAc transferase (OGT) is overexpressed in aggressive prostate cancer. OGT modifies intra-cellul...
O-GlcNAc is a post-translational modification (PTM) of a single N-acetylglucosamine sugar attachment...
O-GlcNAcylation is an important posttranslational modification governed by a single pair of enzymes–...
Post-translational modification of intracellular proteins with a single N-acetylglucosamine sugar (O...
The expression of O-GlcNAc transferase (OGT) and its catalytic product, O-GlcNAcylation (O-GlcNAc), ...
Background: OGT and AMPK collectively target hundreds of intracellular signaling processes, but no s...
The beta-linked N-acetyl-D-glucosamine (GlcNAc) is a posttranslational modification of serine and th...
Elevated O-GlcNAcylation is associated with disease states such as diabetes and cancer. O-GlcNAc tra...
O-GlcNAcylation is a post-translational protein modification overexpressed in the most aggressive pr...
Enormous efforts have been made to target metabolic dependencies of cancer cells for developing new ...
The proteasome is a therapeutic target in cancer, but resistance to proteasome inhibitors often deve...